Fiverr International Ltd vs Merck & Co., Inc. — how do they compare? Fiverr International Ltd trades at $8.76 (market cap $310.61M), while Merck & Co., Inc. trades at $144.59 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 1130.9× Fiverr International Ltd's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Merck & Co., Inc. for 98 Days on average.
| FVRR | MRK | |
|---|---|---|
Market Cap | $310.61M | $351.28B |
Volume | 381,459 | 7,969,665 |
Sector | Media | Health |
52-Week High | $23.60 | $156.43 |
52-Week Low | $8.47 | $82.49 |
Typical Hold Time | 62 Days | 98 Days |
Enterprise Value | $63.00M | $398.04B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.70, up 2.35% on the day, but remains in a bearish technical trend with resistance near $9.00. Recent Q2 2026 earnings missed estimates, with revenue declining 10% year-over-year to $97.8 million, as AI adoption pressures lower-value freelance demand. The company maintains strong gross margins of 82% and trades at discounted valuations, including a P/E of 10.67 and P/S of 0.76. Cash flow trends show operational strength but negative net cash flow in 2025 and 2026.
The outlook is cautious; while valuations are low and profitability is improving, AI disruption and recent earnings misses pose significant headwinds. Analyst consensus is a 'Hold' with a $10.50 price target, reflecting near-term challenges but potential recovery if growth stabilizes. Key risks include competitive threats from AI tools and execution risks in adapting the business model.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →